infect
hepat
c
viru
hcv
remain
major
caus
morbid
mortal
worldwid
despit
recent
advent
highli
effect
directact
antivir
envelop
glycoprotein
hcv
heavili
glycosyl
high
proport
highmannos
glycan
hmg
serv
shield
neutral
antibodi
assist
interact
cellentri
receptor
howev
current
approv
therapeut
target
potenti
druggabl
biomark
investig
therapeut
potenti
lectibodi
avarenfc
avfc
hmgbind
lectinfc
fusion
protein
vitro
assay
show
avfc
capac
neutral
cell
culturederiv
hcv
genotyp
independ
manner
ic
valu
low
nanomolar
rang
histidin
bufferbas
avfc
formul
develop
vivo
studi
use
pxb
human
liver
chimer
mous
model
system
administr
avfc
well
toler
consecut
dose
everi
day
mgkg
signific
chang
bodi
liver
weight
impact
note
blood
human
albumin
level
serum
alanin
aminotransferas
activ
gross
necropsi
liver
patholog
confirm
lack
discern
toxic
treatment
regimen
success
prevent
genotyp
hcv
infect
anim
avfc
mutant
lack
hmg
bind
activ
fail
block
infect
result
suggest
target
envelop
hmg
promis
therapeut
approach
hcv
infect
particular
avfc
may
provid
safe
efficaci
mean
prevent
recurr
infect
upon
liver
transplant
hcvrelat
introduct
hepat
c
viru
hcv
envelop
monopartit
posit
sens
ssrna
viru
inject
mice
jackson
laboratori
barharbor
usa
male
femal
per
time
point
sampl
blood
h
post
inject
concentr
avfc
measur
use
hiv
elisa
briefli
recombin
hiv
nih
aid
reagent
program
coat
overnight
follow
block
dri
milkpbst
serum
sampl
vari
dilut
incub
h
follow
detect
goat
antihuman
fchrp
secondari
antibodi
thermofish
scientif
plasma
concentr
avfc
calcul
interpol
standard
curv
pk
paramet
calcul
use
pksolver
microsoft
excel
avfc
lec
mgkg
dose
avfc
mgkg
dose
treatment
coadminist
ip
viru
inocul
x
copieskg
day
genotyp
strain
everi
day
thereaft
gener
condit
bodi
weight
anim
monitor
everi
day
serum
hcv
rna
blood
halb
measur
everi
day
rtpcr
latex
agglutin
immunonephelometri
lz
test
eiken
ualb
eiken
chemic
co
ltd
respect
serum
alanin
aminotransferas
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
alt
level
determin
either
use
fujifilm
drichem
clinic
chemistri
instrument
elisa
institut
immunolog
co
ltd
tokyo
japan
studi
termin
day
anim
euthan
subject
gross
necropsi
gener
health
blood
also
drawn
via
cardiac
punctur
use
alt
hcv
rna
halb
analys
multipl
comparison
group
time
point
conduct
correct
use
tukey
method
threshold
signific
set
p
liver
bodi
weight
ratio
compar
use
oneway
anova
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
avfc
exhibit
broad
antihcv
activ
vitro
build
previou
observ
avfc
affin
recombin
hcv
envelop
protein
first
examin
whether
avfc
inhibit
hcv
infect
vitro
use
multipl
genotyp
cell
cultureproduc
viru
hcvcc
pseudotyp
viru
hcvpp
avfc
significantli
block
infect
human
liver
cell
line
hcvcc
genotyp
inhibitori
concentr
ic
valu
low
nanomolar
rang
tabl
figur
compar
avaren
monom
avfc
overal
show
approxim
higher
activ
inhibitori
effect
observ
produc
antihiv
broadli
neutral
antibodi
share
human
fc
region
avfc
addit
avaren
avfc
effect
neutral
hcvpp
harbor
murin
leukemia
viru
backbon
suggest
lectin
lectibodi
act
entri
inhibitor
figur
previous
found
avfc
limit
solubl
phosphatebuff
salin
pb
concentr
mgml
unpublish
observ
order
facilit
vivo
studi
screen
optim
liquid
formul
system
administr
impart
improv
stabil
solubl
avfc
higher
concentr
initi
buffer
screen
reveal
avfc
prone
degrad
ph
suggest
avfc
stabl
acid
ph
condit
figur
preformul
studi
led
us
identifi
optim
buffer
compos
mm
histidin
ph
mm
sucros
mm
nacl
although
avfc
show
compar
histidin
buffer
pb
differenti
scan
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
figur
consequ
result
suggest
administr
drug
everi
day
might
suffici
keep
viru
control
murin
hcv
challeng
model
assess
safeti
administr
avfc
effect
discern
potenti
toxic
associ
avfc
hmgbind
activ
includ
avfc
variant
lack
hmgbind
activ
control
avfc
lec
figur
pxb
mice
receiv
either
vehicl
histidin
buffer
describ
total
dose
avfc
mgkg
total
dose
avfc
lecat
mgkg
total
dose
shown
figur
c
signific
differ
either
bodi
weight
blood
halb
level
weight
seen
figur
result
indic
avfc
formul
histidin
buffer
well
toler
immunocompromis
mice
engraft
human
hepatocyt
histopatholog
perform
evalu
potenti
toxic
human
liver
graft
due
avfc
administr
tabl
figur
human
hepatocyt
area
slight
moder
score
tabl
figur
collect
conclud
treatmentrel
advers
effect
liver
tissu
full
patholog
report
may
found
supplementari
inform
lastli
assess
avfc
protect
efficaci
hcv
infect
vivo
use
treatment
regimen
describ
pxb
mice
inocul
ip
genotyp
viru
along
initi
treatment
mgkg
avfc
avfc
lecon
day
shown
figur
avfc
lec
treat
mice
show
high
serum
hcv
rna
level
day
post
challeng
end
studi
day
sharp
contrast
anim
treat
dose
avfc
show
detect
level
hcv
rna
sera
indic
lectibodi
prevent
infect
human
liver
graft
viru
similar
result
figur
overal
major
toxic
signal
note
bodi
weight
halb
halt
level
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
test
group
although
tempor
drop
bodi
weight
halb
one
avfctreat
group
earli
timepoint
indic
liver
graft
remain
function
cours
studi
figur
mechan
hcv
neutral
avfc
like
bind
hmg
envelop
protein
dimer
block
interact
host
cell
receptor
viral
entri
unlik
hiv
envelop
glycoprotein
whose
glycan
content
vari
wide
strain
number
posit
glycosyl
site
highli
conserv
indic
critic
role
hcv
infecti
process
notion
avfc
function
entri
inhibitor
support
fact
lectibodi
affin
protein
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
function
greatli
contribut
antivir
potenc
avfc
hiv
determin
primari
cellbas
inhibit
assay
antibodydepend
cellmedi
viral
inhibit
assay
accordingli
remark
efficaci
seen
present
vivo
hcv
challeng
studi
may
partial
fcmediat
investig
necessari
address
possibl
present
studi
also
demonstr
avfc
therapi
well
toler
mice
human
hepatocyt
ip
administr
mgkg
avfc
dose
show
obviou
toxic
pxb
mice
gross
necropsi
histopatholog
engraft
human
hepatocyt
result
signific
chang
bodi
weight
halb
alt
level
figur
hypothes
lack
signific
toxic
attribut
avfc
uniqu
indic
liver
transplant
us
larg
number
procedur
continu
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
perform
forese
futur
patient
hcvrelat
decompens
cirrhosi
major
outstand
issu
lack
effect
treatment
protect
allograft
liver
recurr
infect
viru
remain
circul
peripheri
time
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
decreas
viral
fit
decreas
incorpor
hcv
particl
increas
suscept
humor
immun
due
breach
glycan
shield
result
provid
foundat
test
hypothes
feasibl
hmgtarget
antihcv
strategi
conclus
present
studi
provid
import
proof
concept
therapeut
potenti
avfc
hcv
infect
via
target
envelop
hmg
particular
lectibodi
may
provid
safe
efficaci
mean
prevent
recurr
infect
upon
liver
transplant
hcvrelat
endstag
liver
diseas
patient
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
histidin
buffer
pb
avfc
prepar
mgml
histidin
buffer
histidin
see
pb
incub
overnight
protein
formul
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
analyz
sdspage
nonreduc
condit
repres
stain
gel
imag
shown
band
around
kda
correspond
avfc
note
overnight
incub
pb
show
less
band
intens
avfc
larges
aggreg
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
safeti
endpoint
note
group
ac
twoway
analysi
varianc
anova
oneway
anova
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
tabl
histiocyt
brown
pigment
glisson
sheath
note
mous
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
fatti
chang
macrovesicular
infiltr
inflammatori
cell
around
vacuol
hepatocyt
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
